Schedule of Contract Assets and Contract Liabilities

Total contract assets at September 30, 2022 were as follows:


(In thousands)	Contract Assets
Contract assets at December 31, 2021	$	13,363
Additions		30,215
Transferred to receivables, net		(33,473	)
Contract assets at September 30, 2022	$	10,105

Total contract liabilities at September 30, 2022 were as follows:


(In thousands)	Contract Liabilities
Contract liabilities at December 31, 2021	$	17,830
Additions		2,595
Amounts recognized into revenue		(5,402	)
Amounts recognized into other (expense) income, net		(6,384	)
Contract liabilities at September 30, 2022	$	8,639

Schedule of Disaggregation of Revenues

During the three and nine months ended September 30, 2022 and 2021, the Company recorded product sales, net, as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2022		2021		2022		2021
VIVITROL	$	96,534	$	88,864	$	277,493	$	251,815
ARISTADA and ARISTADA INITIO		75,719		68,873		222,826		196,693
LYBALVI		27,127		—		61,116		—
Total product sales, net	$	199,380	$	157,737	$	561,435	$	448,508

Schedule of Disaggregation of Revenues

During the three and nine months ended September 30, 2022 and 2021, the Company recorded manufacturing and royalty revenues as follows:


	Three Months Ended September 30, 2022								Nine Months Ended September 30, 2022
(In thousands)	Manufacturing Revenue		Royalty Revenue			Total			Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	26,737		$	26,737		$	—	$	90,439	$	90,439
VUMERITY		5,584		20,666			26,250			22,629		60,386		83,015
RISPERDAL CONSTA		8,380		1,848			10,228			32,529		5,516		38,045
Other		3,265		(13,539	)		(10,274	)		26,472		5,466		31,938
	$	17,229	$	35,712		$	52,941		$	81,630	$	161,807	$	243,437


	Three Months Ended September 30, 2021						Nine Months Ended September 30, 2021
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total		Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	79,323	$	79,323	$	—	$	221,965	$	221,965
VUMERITY		8,499		18,250		26,749		17,671		42,866		60,537
RISPERDAL CONSTA		8,725		2,245		10,970		31,411		8,172		39,583
Other		6,762		12,490		19,252		29,282		47,068		76,350
	$	23,986	$	112,308	$	136,294	$	78,364	$	320,071	$	398,435

(1)

“Long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate)